Medullary thyroid carcinoma arises in the absence of prolactin signaling

Cancer Research

Volumn 65, Issue 18, 2005, Pages 8497-8503

  Kedzia, Cécile ^a   Lacroix, Ludovic ^b   Ameur, Nabahet ^b   Ragot, Thierry ^c   Kelly, Paul A ^a   Caillou, Bernard ^d   Binart, Nadine ^a  

^a INSERM   (France)

^b Unité de Génomique Fonctionnelle   (France)

^c CNRS   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; MEMBRANE RECEPTOR; MESSENGER RNA; PROLACTIN; PROLACTIN RECEPTOR; THYROTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CARCINOGENESIS; CONTROLLED STUDY; HISTOPATHOLOGY; IN SITU HYBRIDIZATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL;

ANIMALS; CARCINOMA, MEDULLARY; FEMALE; MALE; MICE; MUTATION; PROLACTIN; PROTO-ONCOGENE PROTEINS C-RET; RECEPTORS, PROLACTIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID NEOPLASMS;

EID: 24944588250     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3937     Document Type: Article

References (33)

1. Goffin V, Binart N, Touraine P, Kelly PA. Prolactin: the new biology of an old hormone. Annu Rev Physiol 2002;64:47-67.
2. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin and its receptor: actions, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice. Endocr Rev 1998;19:225-68.
3. Ormandy CJ, Binart N, Helloco C, Kelly PA. Mouse prolactin receptor gene: genomic organization reveals alternative promoter usage and generation of isoforms via alternative 3′-exon splicing. DNA Cell Biol 1998;17:761-70.
4. Ormandy CJ, Camus A, Barra J, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 1997;11:167-78.
5. Ling C, Hellgren G, Gebre-Medhin M, et al. Prolactin (PRL) receptor gene expression in mouse adipose tissue: increases during lactation and in PRL-transgenic mice. Endocrinology 2000;141:3564-72.
6. Freemark M, Fleenor D, Driscoll P, Binart N, Kelly PA. Body weight and fat deposition in prolactin receptor-deficient mice. Endocrinology 2001;142:532-7.
7. Clement-Lacroix P, Ormandy C, Lepescheux L, et al. Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. Endocrinology 1999;140:96-105.
8. Vitale G, Caraglia M, Ciccarelli A, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001;91:1797-808.
9. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004;61:299-310.
10. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 1998;48:265-73.
11. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996;276:1575-9.
12. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
13. Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996;81:1619-22.
14. Milhaud G, Tubiana M, Parmentier C, Coutris G. Epithelioma of the thyroid secreting thyrocalcitonin. C R Acad Sci Hebd Seances Acad Sci D 1968:266:608-10.
15. Cohen R, Campos JM, Salaun C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab 2000;85:919-22.
16. Binart N, Helloco C, Ormandy CJ, et al. Rescue of preimplantatory egg development and embryo implantation in prolactin receptor-deficient mice after progesterone administration. Endocrinology 2000;141:2691-7.
17. Weiss RE, Forrest D, Pohlenz J, Cua K, Curran T, Refetoff S. Thyrotropin regulation by thyroid hormone in thyroid hormone receptor β-deficient mice. Endocrinology 1997;138:3624-9.
18. Michiels FM, Chappuis S, Caillou B, et al. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc Natl Acad Sci U S A 1997;94:3330-5.
19. Sowers MF, Hollis BW, Shapiro B, et al. Elevated parathyroid hormone-related peptide associated with lactation and bone density loss. JAMA 1996;276:549-54.
20. Mortensen BM, Gautvik KM, Gordeladze JO. Bone turnover in rats treated with 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 or 24,25-dihydroxyvitamin D3. Biosci Rep 1993;13:27-39.
21. Lippuner K, Zehnder HJ, Casez JP, Takkinen R, Jeager P. PTH-related protein is released into the mothers bloodstream during lactation: evidence for beneficial effects on maternal calcium-phosphate metabolism. J Bone Miner Res 1997;11:1394-9.
22. Hauck SJ, Hunter WS, Danilovich N, Kopchick JJ, Bartke A. Reduced levels of thyroid hormones, insulin, and glucose, and lower body core temperature in the growth hormone receptor/binding protein knockout mouse. Exp Biol Med (Maywood) 2001;226:552-8.
23. Freemark M, Avril I, Fleenor D, et al. Targeted deletion of the prolactin receptor: effects on islet development, insulin production, and glucose tolerance. Endocrinology 2002;143:1378-85.
24. Harman D. The aging process. Proc Natl Acad Sci U S A 1981;78:7124-8.
25. Li J, Teng W, Shan Z. Effects of prolactin on HLA-DR and CD40 expressions by human thyrocytes. Chin Med J (Engl) 2001;114:1151-6.
26. Lu CC, Tsai SC, Huang WJ, Tsai CL, Wang PS. Effects of hyperprolactinemia on calcitonin secretion in male rats. Metabolism 1999;48:221-6.
27. Acton DS, Velthuyzen D, Lips CJ, Hoppener JW. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene 2000;19:3121-5.
28. Jindrichova S, Kodet R, Krskova L, Vlcek P, Bendlova B. The newly detected mutations in the RET protooncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma. J Mol Med 2003;81:819-23.
29. De Miguel M, Fernandez-Santos JM, Trigo-Sanchez I, et al. The Ret proto-oncogene in the WAG/Rij rat strain: an animal model for inherited C-cell carcinoma? Lab Anim 2003;37:215-21.
30. Schuff KG, Hentges ST, Kelly MA, et al. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J Clin Invest 2002;110:973-81.
31. Lee RC, Walters JA, Reyland ME, Anderson SM. Constitutive activation of the prolactin receptor results in the induction of growth factor-independent proliferation and constitutive activation of signaling molecules. J Biol Chem 1999;274:10024-34.
32. Kiya T, Endo T, Goto T, et al. Apoptosis and PCNA expression induced by prolactin in structural involution of the rat corpus luteum. J Endocrinol Invest 1998;21:276-83.
33. Livolsi VA, Feind CR. Incidental medullary thyroid carcinoma in sporadic hyperparathyroidism. An expansion of the concept of C-cell hyperplasia. Am J Clin Pathol 1979;71:595-9.